Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Harvard Bioscience (HBIO) Net Cash Flow (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Net Cash Flow for 16 consecutive years, with $1.8 million as the latest value for Q4 2025.

Quarterly Net Cash Flow rose 1889.8% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Dec 2025, up 10314.29% year-over-year, with the annual reading at $3.6 million for FY2025, 10314.29% up from the prior year.
Net Cash Flow for Q4 2025 was $1.8 million at Harvard Bioscience, up from -$542000.0 in the prior quarter.
The five-year high for Net Cash Flow was $2.4 million in Q4 2021, with the low at -$2.4 million in Q1 2021.
Average Net Cash Flow over 5 years is $1250.0, with a median of $12500.0 recorded in 2024.
The sharpest move saw Net Cash Flow crashed 916.25% in 2021, then soared 1889.8% in 2025.
Over 5 years, Net Cash Flow stood at $2.4 million in 2021, then tumbled by 112.15% to -$286000.0 in 2022, then tumbled by 205.59% to -$874000.0 in 2023, then surged by 88.79% to -$98000.0 in 2024, then skyrocketed by 1889.8% to $1.8 million in 2025.
According to Business Quant data, Net Cash Flow over the past three periods came in at $1.8 million, -$542000.0, and $1.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.